Agalactosyl IgG in inflammatory bowel disease: correlation with C-reactive protein

R Dubé, G A W Rook, J Steele, R Brealey, R Dwek, T Rademacher, J Lennard-Jones

Abstract
The proportion of oligosaccharide chains on the Fc fragment of IgG which terminate with N-acetylgalactosamine (GlcNAc) rather than galactose is increased in rheumatoid arthritis and tuberculosis, and in sera from patients with Crohn’s disease, probably because of decreased activity of a galactosyltransferase in B lymphocytes. We have assayed the prevalence of agalactosyl oligosaccharides on IgG in sera from 67 patients with inflammatory bowel disease (35 ulcerative colitis and 32 Crohn’s disease). The prevalence of agalactosyl IgG significantly increases in the majority of Crohn’s patients (19/35 patients), and correlates with the level of C-reactive protein (r=0.79), and inversely with the concentration of serum albumin. Sera from ulcerative colitis patients show less frequent (nine of 32) and less marked rises in agalactosyl IgG, and sera with high C-reactive protein values can contain normal levels. Thus in ulcerative colitis no correlation was seen between the two assays. The diseases in which the percentage of agalactosyl IgG is raised (rheumatoid arthritis, tuberculosis, Crohn’s disease and some ulcerative colitis) are characterised by simultaneous T cell mediated granulomatous tissue damage, and acute phase responses. Levels are normal in less tissue damaging granulomatous conditions, including sarcoidosis, and leprosy (except during episodes of erythema nodosum leprosum). We suggest therefore that a raised percentage of agalactosyl IgG is a correlate of a particular type of T cell mediated pathology which may be relevant to the pathogenesis of inflammatory bowel disease.

The fact that immunoglobulins are glycoproteins is often ignored. It has become clear, however, that changes in the composition of the sugar components of immunoglobulins correlate with certain clinical states, and may have important functional significance. Thus there is a conserved N-glycosylation site on the Fc of IgG, at asparagine 297 on the CH2 domain. This site bears essentially non-sialylated (90%) branched (biantennary) oligosaccharides, a variable proportion of which bear terminal galactose on one or both of their outer arms. When galactose is not present the terminal sugar is usually N-acetylgalactosamine (GlcNAc). In sera from normal donors the proportion of oligosaccharide chains bearing no terminal galactose (G0) decreases from a level of about 30% in small children to a trough of approximately 20% at the age of 25 years. Then it increases steadily with age to about 40% by 70 years.1 In rheumatoid arthritis there is an increased prevalence of G0 (percent-

age of agalactosyl IgG) which parallels the activity of the disease.23 A rise is also seen in tuberculosis and was found in a preliminary study of a small number of sera from patients with Crohn’s disease.1 These increases are caused by changes in the activity of galactosyltransferase in B lymphocytes.1 Diseases in which no changes in the percentage of agalactosyl IgG are seen include SLE (unless Sjögren’s syndrome is also present), osteoarthritis, multiple sclerosis, Klebsiella infections, myositis, and a range of viral infections.1 Of particular interest is the absence of a raised percentage of agalactosyl IgG in two other granulomatous diseases, sarcoidosis and leprosy, though it rises in the latter during episodes of erythema nodosum leprosum. These disease associations suggest that the percentage of agalactosyl IgG rises when there is both chronic T cell-mediated pathology and an acute phase response.

We confirm here that the percentage of agalactosyl IgG rises in Crohn’s disease, show that it also rises in a minority of patients with ulcerative colitis, and investigate its relationship to clinical and biochemical parameters in both diseases.

Methods

Patients
Between January 1988 and November 1988 sera were collected from 67 patients (33 men, 34 women) who attended the outpatient clinic, or were admitted to the hospital because of exacerbation of their disease. Patients age >60 years were excluded. The group included 35 with Crohn’s disease (16 men, 19 women) and 32 with ulcerative colitis (17 men, 15 women). The diagnosis in all cases had been established by standard clinical, radiological, and histopathological features.

Clinical and biochemical data collected
At the time that serum was obtained for measurement of the percentage of agalactosyl IgG, the following tests were done: full blood count, ESR, C-reactive protein and liver function tests. Other acute phase proteins were measured in a subset of the Crohn’s disease sera. Clinical activity of the disease was also assessed using a slightly modified Harvey-Bradshaw activity index (liquid stool frequency: less than 3, 0; 3 to 5, 1; more than 5, 2).

Monoclonal antibody to terminal N-acetylgalactosamine (GlcNAc)
The monoclonal antibody used for the immuno-
assay of galactosyl IgG has been described elsewhere. Briefly, mice were immunised with group A streptococcal cell wall peptidoglycan/poly saccharide complex, (as the group A polysaccharide bears much terminal GlcNAc), and monoclonals were selected for binding to fetuin treated with enzymes to remove sialic acid and galactose, (asialo-agalacto-fetuin), resulting in exposed terminal GlcNAc. The antibodies were then further screened on agalactosyl IgG.

STANDARDS FOR THE IMMUNOASSAY FOR AGALACTOSYL IgG

Serum and IgG samples of which the galactose values had been obtained by a previously published biochemical procedure were used as standards throughout this study. Briefly, the N-linked oligosaccharides were released from the IgG using anhydrous hydrazine, and purified. The percentage of these oligosaccharides bearing no terminal galactose residues was then determined by measuring the hydrodynamic volume after exposure to an exoglycosidase mixture. The set of standards used was derived from normal donors, tuberculosis, and rheumatoid arthritis patients.

IMMUNOASSAY FOR AGALACTOSYL IgG

Using a template and sharp scalpel, nitrocellulose sheets were shaped into ‘combs’ with 12 teeth, spaced so that each tooth could enter a microtitre well, while the backboard of the comb was supported on the sides of the wells. The entire combs were then incubated for two to three days in protein A (P-6031, Sigma) at 250 µg/ml in phosphate buffered saline. The protein A-coated nitrocellulose was then washed in 1% PBS/Tween for two hours at room temperature.

Serum samples were diluted one in 50 in a buffer consisting of 0·1M glycine and 0·16M NaCl adjusted to pH 7·0 with NaOH to reduce aggregation of IgG. Aliquots of 0·25 ml were placed in flat bottomed microtitre wells in triplicate. The protein A-coated combs of nitrocellulose were placed in these wells and incubated at room temperature for four hours with occasional agitation. Then the combs were removed from the wells, washed twice in 1% BSA, 0·05% Tween 20 in PBS (PBS/BSA/Tween), once in PBS, and fixed in 0·5% glutaraldehyde in PBS for 30 min at 0°C. Fixed combs were washed again in PBS at 4°C containing 0·1M lysine, then boiled for five minutes in PBS in a double waterbath to denature the IgG and expose the sugars.

The nitrocellulose was then incubated on a rocking platform at room temperature for three hours with biotinylated anti-GlcNAc G7 at a dilution of 1/2000 in PBS/BSA/Tween. After careful washing the nitrocellulose was incubated for two hours at room temperature in an avidin/peroxidase complex (Amersham) diluted 1/500 in PBS/BSA/Tween.

Subsequently the binding of peroxidase was revealed with a conventional mixture of hydrogen peroxide and precipitating chromogen (4-chloronaphthol, Sigma) in 5 mM Tris/HCl buffer at pH 7·6 for 15 minutes. After drying the tests were read with a transmitted light photometer adapted from a simple ELISA reader described previously.

CALCULATION OF RESULTS

A curve fitting program (Dataplot, by S M Fraser, Strathclyde University, Glasgow, UK) was used to plot the absorbance values yielded by the standards in the immunooassay, against the percentage of agalactosyl IgG previously determined biochemically. A log linear correlation was found (r=0·94). The same program was used to calculate correlations, and to interpolate values for the unknown sera from patients with ulcerative colitis and Crohn’s disease. Repeat assays of unknown sera gave a mean variation of (±7%).

RESULTS

CHARACTERISATION OF THE PATIENTS STUDIED

Details of the patients studied are shown in Table I. The Crohn’s disease and ulcerative colitis groups were comparable in terms of age, sex ratio, duration of disease and disease activity (Harvey-Bradshaw index for Crohn’s disease (mean (SD)) was 3-3 (1-7); for ulcerative colitis, 2-97 (1-7)).

TABLE 1 Characterisation of the patients studied

<table>
<thead>
<tr>
<th>Crohn’s disease (n = 35)</th>
<th>ulcerative colitis (n = 32)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Mean and range)</td>
<td>34 (16-59)</td>
</tr>
<tr>
<td>History (yr and range)</td>
<td>6 (1-30)</td>
</tr>
<tr>
<td>Site of disease</td>
<td></td>
</tr>
<tr>
<td>Whole colon</td>
<td>2</td>
</tr>
<tr>
<td>Rectum to midtransverse</td>
<td>0</td>
</tr>
<tr>
<td>Left colon</td>
<td>3</td>
</tr>
<tr>
<td>Rectosigmoid</td>
<td>3</td>
</tr>
<tr>
<td>Ileocelecal</td>
<td>9</td>
</tr>
<tr>
<td>Small bowel only</td>
<td>8</td>
</tr>
<tr>
<td>Ileocectomy</td>
<td>2</td>
</tr>
<tr>
<td>Ileocelecal anastomosis</td>
<td>8</td>
</tr>
<tr>
<td>Treatment (age corrected percentage of agalactosyl)*</td>
<td></td>
</tr>
<tr>
<td>Prednisolone only</td>
<td>16 (13.3-14.8)</td>
</tr>
<tr>
<td>5-ASA/sulphasalazine only</td>
<td>8 (8.7-12.1)</td>
</tr>
<tr>
<td>Pred + 5-ASA/sulphasal</td>
<td>4 (14.9-11.8)</td>
</tr>
<tr>
<td>Azathioprine ± other drugs</td>
<td>3 (32.1-2.6)</td>
</tr>
<tr>
<td>No treatment</td>
<td>4 (8.5-6.6)</td>
</tr>
</tbody>
</table>

*Not applicable; +Colon resected; †Terminal ileum resected; ‡Mean increase in percent agalactosyl IgG above the normal values for donors of the same age, in each treatment group (SD).

AGALACTOSYL IgG

Agalactosyl IgG was measured as described. The results are plotted against the age of the donor in Figures 1a, b, because of the known age variation discussed in the introduction. The Figure also shows the mean values for normal donors of the same age and two standard deviations either side of the mean. These normal values were taken from Parekh et al. The percentage of agalactosyl IgG in sera from 19/35 patients with Crohn’s disease fell well above 2xSD, whereas only nine of 32 ulcerative colitis samples did so (and four of these nine patients were borderline, Figure 1b). The difference between the diseases was significant, (p<0.009, Fisher’s exact test) although the distribution of disease activity was similar.
Figure 1: The percentage agalactosyl IgG (GO) for 35 patients with Crohn's disease (Fig 1a) and 32 patients with ulcerative colitis (Fig 1b) plotted against the age of the donor. The black line indicates the mean percentage of agalactosyl for normal donors of the same age. The hatched area shows two standard deviations either side of that mean. Nineteen of 35 patients with Crohn's disease, and nine of 32 patients with ulcerative colitis fall outside the 2×SD.

**Discussion**

The present data confirm that the percentage of agalactosyl IgG markedly rises in Crohn’s disease, and show that this correlates with the rise in C-reactive protein, and the fall in serum albumin in this disease. In contrast, there is no significant rise in the percentage of agalactosyl IgG in the majority of cases of ulcerative colitis, and when there is a rise it does not correlate with C-reactive protein. Thus there are ulcerative colitis patients with striking levels of C-reactive protein who have a normal percentage of agalactosyl IgG, a situation not seen in Crohn’s disease. The clinical associations of raised percentage of agalactosyl IgG discussed in the introduction suggest that this glycosylation change occurs when there is T-cell-dependent granulomatous inflammation with tissue damage and an acute phase response. Thus it is significant that previous authors have noted that the nature of the acute phase response differs in the two diseases. The rise of C-reactive protein is the acute phase response; there are changes in the glycosylation of acute phase proteins secreted by the liver, and cytokines released from macrophages have been implicated in an *in vitro* system. We speculate therefore that a cytokine released from macrophages activated by T cells may also be responsible for the down regulation of galactosyltransferase in B cells which is responsible for the change in glycosylation.

Our previous observations on the clinical correlates of raised agalactosyl IgG, suggest that

**TABLE II** Correlation between age-corrected increases in percent agalactosyl IgG and six clinical parameters

<table>
<thead>
<tr>
<th></th>
<th>Albumin</th>
<th>WBC</th>
<th>Platelets</th>
<th>ESR</th>
<th>Clin Sc*</th>
<th>CRP</th>
<th>α-1--AGP†</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD</td>
<td>0.389†</td>
<td>0.106</td>
<td>0.25</td>
<td>0.335</td>
<td>0.199</td>
<td>0.795</td>
<td>0.69†</td>
</tr>
<tr>
<td>UC</td>
<td>0.306</td>
<td>0.028</td>
<td>0.42‡</td>
<td>0.204</td>
<td>0.306</td>
<td>0.164</td>
<td>ND</td>
</tr>
</tbody>
</table>

*Clinical score (Modified Harvey-Bradshaw); †Alpha-1—acid glycoprotein; ‡p<0.05; §p<0.005; |p<0.01.  

Figure 2: Correlation (r=0.79; p<0.005) between percentage agalactosyl IgG (%GO) and C-reactive protein in the sera of patients with Crohn's disease. In order to correct for variation in the percentage of GO due to age, the mean value of the percentage of GO for normal donors of the same age as each patient has been subtracted.
it rises when there is chronic T cell mediated inflammation leading to, or accompanied by, an acute phase response, but not when there is an acute phase response without such a T cell component. Thus the percentage of agalactosyl IgG rises in rheumatoid arthritis and tuberculosis, both of which are characterised by T cell mediated tissue damage and cytokine release. In rheumatoid arthritis there is release of cytokines such as IL-1, IL-6 and tumor necrosis factor into the joint, and circulation. These mediators are involved either directly or indirectly through release of IL-6, in the induction of the acute phase response. Similarly tuberculosis is accompanied by fever, weight loss, and necrosis in the lesions. This syndrome is readily explained by cytokine release triggered by the mycobacterial lipoarabinomannan. In contrast the percentage of agalactosyl IgG does not rise in sarcoidosis or uncomplicated leprosy where chronic T cell mediated granulomata are not accompanied by T cell mediated tissue damage (though there is damage secondary to nerve compression in leprosy) or a striking acute phase response. When there is an acute episode of T cell mediated pathology and an acute phase response, as during erythema nodosum leprosum, the percentage of agalactosyl IgG rises even in leprosy.

Moreover, because the percentage of agalactosyl IgG was not raised in sera from several acute virus infections, and we have recently found that it is not raised during acute rheumatic fever, and falls during pregnancy (Rook, Whyte et al, in preparation) it is likely that an acute phase reaction without chronic T cell mediated pathology does not lead to the formation of agalactosyl IgG. Thus the difference between Crohn's disease and ulcerative colitis noted in the present study could be related to the known difference in the nature of the acute phase response in the two diseases, or to differences in the nature of T cell function which are suggested by the greater prevalence of granuloma formation in Crohn's disease.

Finally, the occurrence of raised percentage of agalactosyl IgG in tuberculosis, rheumatoid arthritis, and Crohn's disease is provocative as one is a known mycobacterial disease, and these organisms, or autoantigens cross reactive with them, are implicated by some authors in the others.

We are grateful to G D Searle Ltd for financial support.

Agalactosyl IgG in inflammatory bowel disease: correlation with C-reactive protein.

R Dubé, G A Rook, J Steele, R Brealey, R Dwek, T Rademacher and J Lennard-Jones

Gut 1990 31: 431-434
doi: 10.1136/gut.31.4.431